Current Report Filing (8-k)
June 29 2017 - 4:51PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT
REPORT
Pursuant to
Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest
event reported)
June 29,
2017
VistaGen Therapeutics,
Inc.
(Exact name of registrant as
specified in its charter)
Nevada
|
|
000-54014
|
|
20-5093315
|
(State or other
jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
343 Allerton
Ave.
South San
Francisco, California 94090
(Address of principal executive
offices) (Zip Code)
(650)
577-3600
(Registrant’s telephone
number, including area code)
Not
applicable.
(Former name or former address, if
changed since last report)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions (see General Instruction A.2.
below):
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item
2.02
Results of
Operations and Financial Condition.
See Item 8.01.
Today, VistaGen Therapeutics
In
c. (the "
Company
")
issued a press release to provide investors with a corporate update
and to announce the Company's financial results for its fiscal year
ended March 31, 2017. A copy of the press release is attached
hereto as Exhibit 99.1.
The information furnished herein
and therein shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the
“
Exchange
Act
”), or otherwise subject to the liabilities of that
Section, or incorporated by reference in any filing under the
Exchange Act or the Securities Act of 1933, as amended, except as
shall be expressly set forth by specific reference in such
filing.
Item
9.01
Financial
Statements and Exhibits
.
(d) Exhibits
Index
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press release issued by VistaGen
Therapeutics Inc. dated June 29, 2017.
|
Disclaimer.
This Current Report on Form 8-K may
contain, among other things, certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including, without limitation, (i) statements with respect
to the Company's plans, objectives, expectations and intentions;
and (ii) other statements identified by words such as "may",
"could", "would", should", "believes", "expects", "anticipates",
"estimates", "intends", "plans" or similar expressions. These
statements are based upon the current beliefs and expectations of
the Company's management and are subject to significant risks and
uncertainties.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
VistaGen Therapeutics
Inc.
|
Date: June 29,
2017
|
|
|
|
By:
|
/s/ Shawn K.
Singh
|
|
Name:
Title:
|
Shawn K.
Singh
Chief Executive
Officer
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release issued by VistaGen
Therapeutics Inc. dated June 29, 2017.
|
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024